India’s Obesity Market Braces for Price War as Wegovy & Ozempic Generics Arrive
New Delhi – A significant shift is underway in India’s anti-obesity market as pharmaceutical companies prepare to launch more affordable generic versions of the popular weight-loss medications Wegovy and Ozempic. This follows the expiration of the patent for semaglutide, the active ingredient in both drugs, on March 20th, opening the door for increased competition.
Generic Entry Signals a New Era of Accessibility
Over six to seven players, including Sun Pharma, Zydus Lifesciences, Dr Reddy’s, and Natco Pharma, initiated the launch of generic semaglutide on March 21st. More companies are anticipated to enter the market in the coming months, promising a substantial reduction in prices for these previously expensive medications.
Market Growth Anticipated
Analysts predict the approximately ₹1400 crore weight-loss market will double in size within a year. The broader antidiabetic therapy market has already seen strong growth, increasing by over 15% in January, driven by the uptake of innovative therapies like Eli Lilly’s Mounjaro, which recorded sales of ₹112 crore, according to research firm Pharmarack.
Potential Price Reductions
Whereas specific pricing details haven’t been released, experts estimate that generic versions of semaglutide could be priced around 50% lower than the branded options – approximately ₹3,500 to ₹4,000 per month for the starting dose. This price decrease is expected to significantly improve access for patients.
Industry Response and Positioning
Sun Pharma’s Managing Director, Kirti Ganorkar, stated the company is committed to improving access to generic semaglutide across India. Sun Pharma plans to offer its generic versions in an uncomplicated-to-use prefilled pen format and ensure sufficient supply to meet demand. The company is well-positioned to serve both chronic weight management and type 2 diabetes patients.
Innovator Brands Adjusted Pricing
Prior to the generic launches, Novo Nordisk, the maker of Wegovy, reduced the drug’s price by 37% in November, bringing the starting dose down to ₹10,000 per month. Wegovy and Mounjaro were initially launched in India at “India-specific prices” last year, while Ozempic became available in December.
Future Trends & Implications
Increased Competition & Market Share Shifts
The entry of multiple generic manufacturers will intensify competition, potentially leading to further price reductions and a shift in market share. Companies with established chronic disease portfolios are likely to be key players.
Expansion of GLP-1 Market
The increased affordability of semaglutide-based medications is expected to significantly expand the GLP-1 (glucagon-like peptide-1) receptor agonist market in India, benefiting both obesity and type 2 diabetes management.
Focus on Patient Access and Awareness
Pharmaceutical companies and healthcare providers will likely focus on increasing patient awareness about the benefits of GLP-1 medications and ensuring equitable access to these treatments.
FAQ
Q: What is semaglutide?
A: Semaglutide is the active ingredient in both Wegovy and Ozempic, a GLP-1 receptor agonist used for weight management and type 2 diabetes.
Q: What is the difference between Wegovy and Ozempic?
A: Wegovy is specifically approved for weight management, while Ozempic is approved for treating type 2 diabetes. Wegovy also contains a higher dose of semaglutide.
Q: When did the patent for semaglutide expire?
A: The patent expired on March 20th.
Q: How much cheaper will generic semaglutide be?
A: Analysts estimate generic versions could be around 50% cheaper than branded options.
